We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-6.61%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$670M
AUM Growth
+$109M
(+19%)
Cap. Flow
+$144M
Cap. Flow
% of AUM
21.49%
Top 10 Holdings %
Top 10 Hldgs %
59.4%
Holding
184
New
14
Increased
76
Reduced
55
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
+$71.8M |
| 2 |
WPZ
Williams Partners L.P.
WPZ
|
+$17.8M |
| 3 |
BPL
Buckeye Partners, L.P.
BPL
|
+$15M |
| 4 |
Enterprise Products Partners
EPD
|
+$13.8M |
| 5 |
Energy Transfer Partners
ET
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$45.5M |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$34.1M |
| 3 |
Marathon Petroleum
MPC
|
+$6.13M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$4.81M |
| 5 |
ProShares Ultra S&P500
SSO
|
+$4.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 73.91% |
| 2 | Healthcare | 7.71% |
| 3 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Insmed
INSM
$23.3B
| $324K | 0.05% |
18,896
-2,986
| -14% | -$51K |
|
|
ACHN
102
DELISTED
Achillion Pharmaceuticals
ACHN
| $323K | 0.05% |
70,350
+900
| +1% | +$3.62K |
|
103
Novavax
NVAX
$1.29B
| $322K | 0.05% |
14,004
+3,156
| +29% | +$61.9K |
|
|
PRTK
104
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $322K | 0.05% |
13,379
-6,830
| -34% | -$151K |
|
|
ARRY
105
DELISTED
Array Biopharma Inc
ARRY
| $321K | 0.05% |
38,373
+6,350
| +20% | +$51.9K |
|
|
LOXO
106
DELISTED
Loxo Oncology, Inc
LOXO
| $321K | 0.05% |
4,009
-6,399
| -61% | -$355K |
|
107
Alnylam Pharmaceuticals
ALNY
$35.9B
| $320K | 0.05% |
4,007
-2,471
| -38% | -$158K |
|
108
Corbus Pharmaceuticals
CRBP
$173M
| $320K | 0.05% |
1,693
+608
| +56% | +$119K |
|
|
LJPC
109
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $320K | 0.05% |
10,761
-5,087
| -32% | -$146K |
|
|
KDNY
110
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $318K | 0.05% |
5,576
+464
| +9% | +$23.3K |
|
|
ARAV
111
DELISTED
Aravive, Inc. Common Stock
ARAV
| $317K | 0.05% |
+3,027
| New | +$325K |
|
112
Geron
GERN
$930M
| $316K | 0.05% |
113,952
-23,243
| -17% | -$61.8K |
|
|
CALA
113
DELISTED
Calithera Biosciences, Inc
CALA
| $315K | 0.05% |
+1,059
| New | +$283K |
|
114
Celldex Therapeutics
CLDX
$2.78B
| $314K | 0.05% |
8,466
+3,450
| +69% | +$153K |
|
115
Rigel Pharmaceuticals
RIGL
$681M
| $313K | 0.05% |
11,483
+243
| +2% | +$6.65K |
|
116
Regenxbio
RGNX
$656M
| $310K | 0.05% |
+15,691
| New | +$304K |
|
|
SAGE
117
DELISTED
Sage Therapeutics
SAGE
| $306K | 0.05% |
3,846
-1,991
| -34% | -$144K |
|
118
Neurogene
NGNE
$710M
| $305K | 0.05% |
1,084
+180
| +20% | +$51.5K |
|
119
Xencor
XNCR
$1.45B
| $305K | 0.05% |
14,429
+3,079
| +27% | +$69K |
|
|
XLRN
120
DELISTED
Acceleron Pharma
XLRN
| $303K | 0.05% |
9,973
+272
| +3% | +$7.88K |
|
121
Ultragenyx Pharmaceutical
RARE
$2.66B
| $302K | 0.05% |
4,855
+883
| +22% | +$53.2K |
|
122
Agios Pharmaceuticals
AGIO
$2.16B
| $301K | 0.04% |
5,847
+578
| +11% | +$29.5K |
|
123
Akebia Therapeutics
AKBA
$327M
| $301K | 0.04% |
+20,913
| New | +$265K |
|
|
FPRX
124
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $300K | 0.04% |
9,963
+4,335
| +77% | +$135K |
|
|
SIOX
125
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $298K | 0.04% |
1,607
-1,181
| -42% | -$207K |
|
Similar funds
NCM
OC
SSA
LIWM
VFG
IAM
1M
GC
Virtus ETF Advisers's Q2 2017 Portfolio in Review
As of Q2 2017, Virtus ETF Advisers held 184 positions worth $670M, up 19% from $562M the previous quarter. Its ten largest holdings account for 59% of the portfolio.
Virtus ETF Advisers deployed $144M of net new capital in Q2 2017, opening 14 new positions and adding to 76 existing holdings. Its largest new stake was Jounce Therapeutics, Inc. Common Stock: 18,442 shares worth $259K.
By sector, the portfolio is most concentrated in Energy at 74% of assets, up from 70% a quarter earlier, followed by Healthcare and Utilities.
On the sell side, the largest reduction was Marathon Petroleum, an estimated $6.13M trimmed.
- Virtus ETF Advisers's largest Q2 2017 buy was Jounce Therapeutics, Inc. Common Stock: 18,442 shares worth $259K.
- Virtus ETF Advisers added most to Energy Transfer Partners, L.P. in Q2 2017, an estimated $71.8M increase.
- Virtus ETF Advisers's biggest Q2 2017 reduction was Marathon Petroleum, cutting an estimated $6.13M.
- Virtus ETF Advisers fully exited Energy Transfer Partners L.p. in Q2 2017, selling an estimated $45.5M.
- Virtus ETF Advisers's ten largest holdings make up 59% of its $670M portfolio in Q2 2017.
- Virtus ETF Advisers opened 14 new positions and closed 39 in Q2 2017.
- Virtus ETF Advisers's portfolio value rose 19% quarter-over-quarter to $670M.
Based on Virtus ETF Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.